Molecular Partners Ag (MOLN) Non-Current Assets (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Non-Current Assets of $6040.2 for Q1 2026, up 31.05% year-over-year from $4609.2 in Q1 2025, and down 7.71% quarter-over-quarter from $6544.9 in Q4 2025.
Molecular Partners Ag (MOLN) Non-Current Assets (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Non-Current Assets for 7 consecutive years, with $6040.2 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets rose 31.05% year-over-year to $6040.2; the TTM figure through Mar 2026 stood at $6040.2 (up 31.05% YoY), while the FY2025 annual figure was $6544.9, up 35.0% from the prior year.
- Non-Current Assets retreated to $6040.2 in Q1 2026 per MOLN's latest filing, from $6544.9 in the prior quarter.
- Across five years, Non-Current Assets topped out at $8.1 million in Q2 2022 and bottomed at $3987.8 in Q3 2025.
- Historically, Non-Current Assets has averaged $1.2 million across 5 years, with a median of $6643.5 in 2023.
- On a YoY basis, Non-Current Assets climbed as much as 35.0% in 2025 and fell as far as 99.92% in 2025.
- Molecular Partners Ag's Non-Current Assets stood at $7791.4 in 2022, then decreased by 14.73% to $6643.5 in 2023, then dropped by 27.03% to $4848.0 in 2024, then soared by 35.0% to $6544.9 in 2025, then declined by 7.71% to $6040.2 in 2026.
- Business Quant data shows MOLN's Non-Current Assets at $6040.2 in Q1 2026, $6544.9 in Q4 2025, and $3987.8 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 18.06 Bn |
| 10 | Molecular Partners Ag | 163.99 Mn | 163.99 Mn | - | 6,040.23 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6,040.23 |
| Dec 31, 2025 | 6,544.87 |
| Sep 30, 2025 | 3,987.85 |
| Jun 30, 2025 | 4,452.28 |
| Mar 31, 2025 | 4,609.17 |
| Dec 31, 2024 | 4,848.04 |
| Sep 30, 2024 | 5,401.69 |
| Jun 30, 2024 | 5.54 Mn |
| Mar 31, 2024 | 6,208.45 |
| Dec 31, 2023 | 6,643.50 |
| Sep 30, 2023 | 7,002.36 |
| Jun 30, 2023 | 7.38 Mn |
| Mar 31, 2023 | 7,627.60 |
| Dec 31, 2022 | 7,791.39 |
| Sep 30, 2022 | 7,741.07 |
| Jun 30, 2022 | 8.11 Mn |
| Mar 31, 2022 | 8,915.84 |
| Dec 31, 2021 | 9,193.32 |
| Sep 30, 2021 | 9,489.58 |
| Dec 31, 2020 | 10,767.32 |